Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07197827 · ClinicalTrials.gov registry record · Phase 1

A Study of YL242 in Subjects With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..

Recruiting
Registry status
Phase 1
Development phase
424
Enrollment target
15
Study locations

NCT07197827 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 424 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (122% higher). The trial reports 15 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07197827, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..

RECRUITING
Registry status
Phase 1
Development phase
424 participants
Enrollment target
15
Study locations

Study Summary

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG YL242
  • DRUG YL242; Pembrolizumab
  • DRUG YL242; 5-FU; LV
  • DRUG YL242; Pembrolizumab; 5-FU

Study Locations (15)

Victoria

  • AUS-102 - Darlinghurst
  • AUS-104 - Fitzroy
  • AUS-103 - Heidelberg

Texas

  • US-203 - Houston
  • US-207 - San Antonio

Connecticut

  • US-201 - New Haven

Florida

  • US-202 - Sarasota

Massachusetts

  • US-204 - Boston

Michigan

  • US-206 - Grand Rapids

Tennessee

  • US-205 - Nashville

New South Wales

  • AUS-101 - Liverpool

Trial Details

FieldValue
Enrollment Target 424 participants
Start Date 2025-09-22
Est. Completion 2028-11
Phase Phase 1

Sponsor

MediLink Therapeutics (Suzhou) Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07197827

The ClinicalTrials.gov registry entry for NCT07197827 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (122% higher). The listed sponsor is MediLink Therapeutics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which YL242 is the first listed.

NCT07197827 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Victoria, Texas, Connecticut.

Frequently Asked Questions

What is clinical trial NCT07197827 about?

NCT07197827 is a clinical study titled "A Study of YL242 in Subjects With Advanced Solid Tumors". This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

What is the current status of trial NCT07197827?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 424 participants. The study started on 2025-09-22. Estimated completion is 2028-11.

What conditions does trial NCT07197827 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT07197827?

The interventions under investigation include: YL242 (DRUG), YL242; Pembrolizumab (DRUG), YL242; 5-FU; LV (DRUG), YL242; Pembrolizumab; 5-FU (DRUG).

Who is sponsoring clinical trial NCT07197827?

This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07197827 being conducted?

This trial has 15 study locations across Connecticut, Florida, Massachusetts, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.